Why Intra-Cellular Therapies’ Depression Study Is Nothing to Smile About
Intra-Cellular Therapies has announced top-line results from its two late-stage trial in patients with bipolar depression.
Intra-Cellular Therapies has announced top-line results from its two late-stage trial in patients with bipolar depression.
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.
Pfizer shares were up slightly on Monday after the firm announced topline results from its most recent late-stage study in young children with mild to moderate atopic dermatitis, also known as eczema.
Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
Avid Bioservices beat expectations around earnings, and it is adding customers and growing its backlog. One analyst has just reversed a prior downgrade and now believes that Avid shares could nearly double, even after…
Adaptive Biotechnologies entered the market with a bang on Thursday, well above the high end of the expected price range.
Private equity firm Centerbridge Partners is reportedly discussing an acquisition of health care provider Magellan Health. While not on the same scale as recent mega-mergers in the sector, this might be another building block…
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Aclaris Therapeutics shares sharply dropped early on Thursday after the firm announced results from its midstage trial in alopecia areata.
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
A recent report shows that in some American cities, the lifespan can be nearly 30 years longer in one neighborhood than in another.
The June 14 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Allergan shares jumped on Tuesday after the company announced that it would be acquired by AbbVie in a cash and stock transaction valued at roughly $63 billion.
Akorn shares dipped on Tuesday after the firm announced that it received a warning letter from the FDA related to the inspection of its Somerset, New Jersey, manufacturing facility in July and August of…
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.